Influence of Hydration Status on the Yield of Injectable Platelet-Rich Fibrin (T-PRF)

March 27, 2026 updated by: Medical University of Graz

Influence of the Drinking Amount on the Autologous Blood in the Centrifuge Contained Fibrin Matrix - Platelet-rich Fibrin A Randomized Controlled Pilot Study

Due to the current lack of evidence regarding the influence of fluid intake on the amount of leukocyte- and platelet-rich fibrin fraction present in blood samples, this study aims to investigate the positive influence of this factor on the body's own matrix.

Platelet-rich fibrin, a fibrin-rich autologous matrix obtained from autologous blood via centrifugation, contains not only fibrin but also important growth factors and a large number of white blood cells, all of which make a significant contribution to tissue regeneration. The obtained fibrin matrix can be used as a membrane, as a clot (A-PRF), or as a liquid (i-PRF) to positively influence the healing process.

The novelty of this work lies in shifting the focus from purely technical centrifugation parameters to a patient-centered, easily modifiable biological variable. Hydration status represents a low-cost, non-invasive, and immediately applicable strategy to optimize autologous blood concentrates. These findings are directly relevant to clinicians seeking to enhance the predictability and efficiency of PRF-based regenerative procedures in implant dentistry.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
    • Styria
      • Graz, Styria, Austria, 8010
        • Medical University of Graz

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- Healthy adults

Exclusion Criteria:

  • coagulation disorders
  • anticoagulant medication
  • pregnancy
  • acute infections
  • systemic diseases with the potential to affect wound healing or blood composition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hydration
Drinking protocol to reach euhydration
Behavioral: Hydration following a drinking protocol
Participants followed a drinking protocol the day before the measurement to reach euhydration

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PRF-Volume
Time Frame: 3 visits, 3 weeks
Volume (ml) of i-PRF obtained from each 10 ml blood sample with low speed centrifugation
3 visits, 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PRF yield and height
Time Frame: 3 visits, 3 weeks
Correlation of PRF yield in ml and height in cm
3 visits, 3 weeks
PRF yield and weight
Time Frame: 3 visits, 3 weeks
Correlation of PRF yield in ml and weight in kg
3 visits, 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Graz

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 12, 2022

Primary Completion (Actual)

May 19, 2023

Study Completion (Actual)

May 19, 2023

Study Registration Dates

First Submitted

March 17, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 1, 2026

Study Record Updates

Last Update Posted (Actual)

April 1, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 34-508 ex 21/22

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data will be shared upon reasonable request. Data sheets containing anonymized measurements, sorted by outcome variable, can be shared. To request this, please contact us via email and explain your reason for wanting the data. The data will be shared personally; no public link will be provided.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Behavior Change Interventions

Clinical Trials on Hydration following a drinking protocol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe